October 28th, 2025 | 07:15 CET
Better than BioNTech, Evotec & Co.? BioNxt Solutions faces key milestones and is considering an AI takeover – Stock in an upward trend
An exciting alternative to Evotec, BioNTech, and similar companies is BioNxt Solutions. The Canadian-German company's business model is a refreshing departure from traditional biotech companies with their huge research costs. BioNxt reformulates already approved active ingredients. For instance, Ozempic is set to be taken orally instead of by injection in the future. The sublingual cladribine formulation for multiple sclerosis is already well advanced, with its preclinical phase nearing completion. At the same time, CEO Hugh Rogers is considering an acquisition in the field of artificial intelligence to further accelerate development processes. The aforementioned development in the billion-dollar obesity market is also exciting. If a breakthrough succeeds, the Company could soon become a takeover candidate for Big Pharma.
time to read: 2 minutes
|
Author:
Fabian Lorenz
ISIN:
Bionxt Solutions Inc. | CA0909741062
Table of contents:
Author
Fabian Lorenz
For more than twenty years, the Cologne native has been intensively involved with the stock market, both professionally and privately. He is particularly passionate about national and international small and micro caps.
Tag cloud
Shares cloud
Business model: Manageable, diversified, and scalable
In an interview with the International Investment Forum (IIF), CEO Hugh Rogers emphasized BioNxt Solutions' unique positioning in the biotech sector. He hinted at a potential acquisition in the field of artificial intelligence. Unlike many of its competitors, the Company does not develop completely new active ingredients. Instead, it reformulates already approved drugs using its proprietary sublingual, orally dissolvable platform technology. This approach reduces development risks, saves time and costs, and accelerates the path to market maturity. While conventional biotech projects often take more than 10 years and require over USD 100 million, Rogers stated that BioNxt can bring new products to market within just 2 to 4 years — and at a fraction of the cost.
Cladribine formulation in the critical phase
The first key project is a sublingual cladribine formulation for the treatment of multiple sclerosis and other autoimmune diseases. The dissolvable thin-film is designed to make administration significantly easier for patients. Patent applications in key international markets such as the European Union, Canada, Australia, Eurasia, New Zealand, and Japan are already underway, as is a Track One priority application in the US. The large-scale crossover bioequivalence study in animals is expected to be completed in November, with results available in December. Before the comparative bioequivalence study in humans begins next year, the goal is to obtain critical data to optimize the drug dose and assess the potentially significantly higher bioavailability.
https://youtu.be/nAHuxxf-zss?si=263H6EXJonVzzYnA
Commercialization via licensing or acquisition by big pharma
Regarding the long-term strategy, CEO Hugh Rogers stated that BioNxt intends to focus on research, patents, and early clinical development. Subsequent commercialization is planned through licensing agreements or acquisitions by larger pharmaceutical companies. With its platform technology and intellectual property rights, Rogers believes the Company is "well-positioned for potential deals." BioNxt is therefore positioning itself as an agile biotech company that combines innovation with economic efficiency, thereby bridging the gap between academic research and industrial-scale production. BioNxt could also rely on artificial intelligence (AI) for further development in the future. To this end, a potential acquisition in North America is currently under consideration.
In the spotlight of Big Pharma: Sublingual thin-film for Ozempic
Another promising candidate from BioNxt is the sublingual thin-film formulation of Ozempic (semaglutide). This innovative approach aims to disrupt the multi-billion-dollar obesity market, one of the most dynamic sectors in the pharmaceutical industry. According to analysts, companies like Novo Nordisk and Eli Lilly & Co. could generate annual sales of around USD 150 billion by the end of the decade. Until now, almost all preparations have had to be injected – an obstacle for many patients. BioNxt's goal is to develop an oral dosage form that absorbs the active ingredient through the oral mucosa. If this step is successful, a patent could soon follow – a milestone that would make the Company highly attractive for partnerships with industry giants or even potential acquisitions.
BioNxt CEO Hugh Rogers provided an exciting insight into the Company in an IIF interview. The strategy appears compelling, with the cladribine formulation potentially becoming the first in-house development to be partnered soon, and the stock is also showing sustainable positive performance.
Conflict of interest
Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.
In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.
For this reason, there is a concrete conflict of interest.
The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.
Risk notice
Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.
The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.
The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.
